

ATTORNEYS AT LAW



Robert Greene Sterne Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michele A. Cimbala Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Horner Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim

Patrick E. Garrett
Jeffrey T. Helvey
Heidi L. Kraus
Eldora L. Ellison
Thomas C. Fiala
Donald R. Banowit
Peter A. Jackman
Jeffrey S. Weaver
Brian J. Del Buono
Edward W. Yee
Vincent L. Capuano
Virgil Lee Beaston
Theodore A. Wood
Elizabeth J. Haanes
Joseph S. Ostroff
Frank R. Cottingham
Rae Lynn P. Guest
Daniel A. Klein

July 26, 2006

Michael D. Specht
Tracy L. Muller
Jon E. Wright
LuAnne M. DeSantis
Ann E. Summerfield
Helene C. Carlson
Cynthia M. Bouchez
Timothy A. Doyle
Gaby L. Longswort
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Bashir M.S. Ali
Shannon A. Carroll
Matthew E. Kelley
Michelle K. Holoubek
Marsha A. Rose

Jason D. Eisenberg

Young Tang Christopher J. Walsh W. Blake Coblentz\* James J. Pohl\* John T. Haran\* Mark W. Rygiel Kevin W. McCabe Registered Patent Ag

Registered Patent Agents
Karen R. Markowicz
Matthew J. Dowd
Katrina Yujian Pei Quach
Bryan L. Skelton
Robert A. Schwartzman
Victoria S. Rutherford
Simon J. Elliott
Julie A. Heider
Mita Mukherjee

Scott M. Woodhouse Liliana Di Nola-Baron Peter A. Socarras Jeffrey K. Mills Danielle L. Letting Lori Brandes Steven C. Oppenheimer

Of Counsel Edward J. Kessler Kenneth C. Bass III Marvin C. Guthrie

\*Admitted only in Maryland \*Admitted only in Virginia \*Practice Limited to Federal Agencies

WRITER'S DIRECT NUMBER: (202) 772-8637 INTERNET ADDRESS: KARENM@SKGF.COM

Art Unit 1643

Attn: Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 10/623,813; Filed: July 22, 2003

For: De novo DNA Cytosine Methyltransferase Genes, Polypeptides and

**Uses Thereof** 

Inventors:

LI et al.

Our Ref:

0609.4560003/KRM/DJN

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Reply to Restriction Requirement; and
- 2. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Kaur P. Madowicz

Karen R. Markowicz Agent for Applicants Registration No. 36,351

KRM/DJN/jk Enclosures

\$62447 Sterne, Kessler, Goldstein & Fox P.L.L.c. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

LI et al.

Appl. No.: 10/623,813

Filed: July 22, 2003

For: De novo DNA Cytosine

Methyltransferase Genes, Polypeptides and Uses Thereof Confirmation No.: 2332

Art Unit: 1643

Examiner: Harris, Alana M.

Atty. Docket: 0609.4560003/KRM/DJN

## **Reply to Restriction Requirement**

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

In reply to the Office Action dated June 26, 2006, requesting an election of one invention to prosecute in the above-referenced patent application, Applicants hereby provisionally elect to prosecute the invention of Group XVII, which is represented by claims 38-42 and 45-49, and corresponds to part (b) of claim 38, *viz.*, a polynucleotide sequence encoding a polypeptide comprising amino acids from about 1 to about 689 in SEQ ID NO:86. This election is made without prejudice to or disclaimer of the other claims or inventions disclosed.

This election is made with traverse.

Applicants respectfully request the Examiner to reconsider the claim grouping as now presented based on the following comments:

<sup>&</sup>lt;sup>1</sup> Applicants election is based on the Examiner's statement on p. 2, lines 1-3 of the Office Action, that "Applicants are put on notice that each sequence, SEQ ID number and ATCC Deposit number reads on an independent and distinct invention and that is reflected in the following requirement."

Groups XVI and XVII are drawn to polynucleotides that encode mouse or human Dnmt3a2 polypeptide, respectively. Groups XXII and XXIII are drawn to polynucleotides contained in ATCC Deposits that encode mouse or human Dnmt3a2 polypeptide, respectively. Thus, at a minimum, Groups XVII and XXIII should be rejoined because they both correspond to polynucleotide sequences that encode the human Dnmt3a2 polypeptide. For the same reasons, Groups XVI and XXIII should be rejoined because they both correspond to polynucleotide sequences that encode the mouse Dnmt3a2 polypeptide.

Moreover, Applicants further submit that it would not be undue to search both mouse and human Dnmt3a2 sequences together, as these sequences are homologs and exhibit very high identity, as indicated by the specification:

[a]n alignment of the human and murine cDNA sequences reveals strong similarity (Fig. 13E1-E4) except that human DNMT3A2 contains an additional sequence of 68 bp in the 5'UTR, which is encoded by an extra exon located ~2.5 kb downstream of exon 7 (the newly identified exons are indicated by \* in Fig. 12A). The predicted mouse Dnmt3a2 and human DNMT3A2 proteins, each consisting of 689 amino acids (Fig. 13B and D, respectively), show high sequence identity (Fig. 13F; 98.5%).

See specification, p. 90, paragraph [0269]. Thus, a search for polynucleotide sequences encoding human DNMT3A2 polypeptide would encompass a search for polynucleotide sequences encoding mouse Dnmt3a2. Accordingly, Applicants further respectfully request that Groups XVII and XXIII be rejoined with Groups XVII and XXII.

Reconsideration and withdrawal of the Restriction Requirement, and consideration and allowance of all pending claims, are respectfully requested.

It is not believed that extensions of time are required, beyond those that may otherwise be provided for in accompanying documents. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor are hereby authorized to be charged to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Karen R. Markowicz Agent for Applicants Registration No. 36,351

Date: <u>July 26, 2006</u>

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

561498